Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense therapy for lymphomas

F E Cotter1

  • 1Molecular Haematology Unit, Institute of Child Health, London, U.K.

Hematological Oncology
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotides (AO) show promise for downregulating oncogenes in lymphoma, potentially overcoming chemotherapy resistance. Further research is needed to improve AO delivery and reduce toxicity for enhanced cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromosome 7 and Haematological Malignancies.

Hematology (Amsterdam, Netherlands)·2016
Same author

Antisense Oligonucleotides: Considerations for Lymphoma Therapy.

Hematology (Amsterdam, Netherlands)·2016
Same author

RT-PCR Analysis of Breakpoints Involving the MLL Gene Located at 11q23 in Acute Leukemia.

Methods in molecular medicine·2011
Same author

Genetic alteration associated with chronic lymphocytic leukemia.

Cytogenetic and genome research·2007
Same author

Stochastic modelling of apoptosis kinetics.

Apoptosis : an international journal on programmed cell death·2005
Same author

Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells.

Gut·2002
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Antisense oligonucleotides (AO) offer a potential strategy for targeted gene silencing.
  • Oncogenes play a critical role in the development and progression of lymphomas.
  • Chemotherapy resistance remains a significant challenge in treating lymphoma and other malignancies.

Purpose of the Study:

  • To evaluate the potential of antisense oligonucleotides to downregulate oncogene expression in lymphoma.
  • To explore the combination of antisense therapy with chemotherapy to overcome drug resistance.
  • To identify strategies for improving AO delivery and reducing associated toxicities.

Main Methods:

  • Gene silencing using antisense oligonucleotides targeting oncogenes like BCL-2 and MYC.

Related Experiment Videos

  • In vitro and in vivo efficacy studies of AO in lymphoma models.
  • Investigation of combination therapies involving AO and conventional chemotherapy.

    • Main Results:

    • Antisense oligonucleotides demonstrate the ability to downregulate oncogene expression in lymphomas.
    • In vitro and in vivo studies confirm the efficacy of AO.
    • Potential for combining AO with chemotherapy to overcome resistance in high BCL-2 expressing malignancies.

    Conclusions:

    • Antisense oligonucleotides represent a promising therapeutic approach for lymphomas and other cancers.
    • Improving AO cellular uptake and developing safer oligonucleotide generations are crucial for clinical application.
    • Targeted gene silencing via AO holds potential for improving patient treatment outcomes in malignancies.